The Quantellect read.As of Nov 19, 2026, 5 active firms cover Unicycive Therapeutics Inc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $13.00 to $50.00 (about 3.8x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $24.60 sits 588% above the current $3.58. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.20 next quarter toward $0.92 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$24.60
+588.1% upside
Average target across 5 active firms as of Nov 19, 2026 vs $3.58 current
Highest Target$50.00
Average Target$24.60
Lowest Target$13.00
Detailed analyst forecasts for UNCY
Showing 1–6 of 6 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate UNCY a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
UNCY EPS & revenue forecast
EPS · NEXT QUARTER
$-0.20
Range $-0.43 – $0.31 · 6 analysts
Next period, 6 analysts expect Unicycive Therapeutics Inc to earn $-0.20 a share (range $-0.43 – $0.31), versus — a year earlier. Full-year consensus is $-1.26, growing to $0.92 the year after.
REVENUE · NEXT QUARTER
$12.6M
Range $-140.0K – $44.4M · 6 analysts
Revenue is expected to reach $12.6M (range $-140.0K – $44.4M). Full-year consensus is $1.3M, rising to $112.1M next year.
Top analysts covering Unicycive Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on UNCY.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$20.00+459.4% to target
Overall win rate
49%
+ Follow
#2
Ed Arce
HC Wainwright & Co. · Rank #168
Buy
$7.50+109.8% to target
Overall win rate
44%
+ Follow
#3
Vamil Divan
Guggenheim · Rank #211
Buy
$25.00+599.3% to target
Overall win rate
48%
+ Follow
#4
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #321
Buy
$13.00+263.6% to target
Overall win rate
38%
+ Follow
#5
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$90.00+2417.5% to target
Overall win rate
30%
+ Follow
UNCY stock forecast FAQ
What is UNCY's average 12-month price target?+
The 5 active firms with a live target average $24.60 for Unicycive Therapeutics Inc over the next 12 months, ranging from a $50.00 high to a $13.00 low, as of Nov 19, 2026.
Is UNCY stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for UNCY?+
The Street-high target is $50.00 (Noble Capital Markets), and the Street-low is $13.00 (HC Wainwright & Co.). The average of all 5 active-firm targets is $24.60.
How many active Wall Street firms cover UNCY?+
5 active firms have a recognized rating on Unicycive Therapeutics Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering UNCY?+
Among analysts who currently cover UNCY, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $20.00 target.
What is Unicycive Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.20 per share (range $-0.43 – $0.31) across 6 analysts. Full-year EPS is projected at $-1.26, rising to $0.92 the following year.
How much revenue is Unicycive Therapeutics Inc expected to report next quarter?+
Consensus revenue is $12.6M (range $-140.0K – $44.4M). Full-year revenue is projected at $1.3M, growing to $112.1M next year.
Have analysts been upgrading or downgrading UNCY lately?+
As of Nov 19, 2026, 5 of 5 active firms rate UNCY a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their UNCY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.